PUBLICATIONS
PRECISION MEDICINE
Engineering Level Molecular Diagnosis: A Necessity for Cancer Treatment (and for Moonshot Success) MP Castro. Cancer Letter, July 21, 2023. Vol.49 No.29; https://cancerletter.com/trials-and-tribulations/20230721_7/#:~:text=ClinicalTrials%20%26%20Tribulations-,Engineering%2Dlevel%20molecular%20diagnosis%3A%20A%20necessity%20for%20cancer%20treatment%E2%80%94,and%20for%20a%20successful%20Moonshot&text=The%20initial%20foray%20into%20genomic,management%20of%20imminently%20lethal%20diseases
NEURO-ONCOLOGY
Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma: results from a nationwide real-world evidence database. MP Castro, T Stuhlmiller, et al. Neuro-Oncology Practice, 2024;, npae044, https://doi.org/10.1093/nop/npae044
Network targeting combination therapy (NTCT) of synthetic lethal (SL) vulnerabilities in 9p21 deficient glioblastoma (GBM): a case report. Michael P Castro, Kristin Dittmar. Neuro-Oncology Advances, 2023; vdad162, https://doi.org/10.1093/noajnl/vdad162
Network-targeting combination therapy (NTCT) of leptomeningeal glioblastoma (LM-GBM) using multiple synthetic lethal strategies: a case report. Castro MP, Sipos B, Biskup S, Kahn N. (2023) Front. Oncol. 13:1210224. doi: 10.3389/fonc.2023.1210224
Use of proton pump inhibitors (PPI) in glioblastoma (GBM) is detrimental to overall survival in a national real-world evidence (RWE) database. Michael P. Castro, Jameson Quinn, Asher Wasserman, Mark Shapiro, Timothy J. Stuhlmiller, Santosh Kesari. J Clin Oncol, 2023 41(16_suppl) e14027-e14027. 10.1200/JCO.2023.41.16_suppl.e14027
Targeting the Complex Protein Network of MYCN-amplified Anaplastic Ependymoma: A Case Report. Castro MP. J Cell Signal. 2022;3(4):179-192.
EPCO-06. The impact of mismatch repair deficiency (MMRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma. MP Castro, F Iwamoto, M Ahluwalia, et al., Neuro-Oncology, 2022, 24(7): vii116-vii117, https://doi.org/10.1093/neuonc/noac209.441
Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy—a case report. Castro MP, Khanlou N, Fallah A, Pampana A, Alam A, Lala DA, Roy KGG, Amara ARR, Prakash A, Singh D, Behura L, Kumar A, Kapoor S. Ann Transl Med 2022 https://dx.doi.org/10.21037/atm-2022-62
Unintended effects of proton pump inhibitors (PPIs) in patients with glioblastoma (GBM): A double-edged sword. MP Castro, Neuro-Oncology Practice, 2022, 9(4): 344-45, https://doi.org/10.1093/nop/npac035
Predictions of overall survival (OS) and progression-free survival (PFS) for specific therapeutic interventions in newly diagnosed glioblastoma multiforme (GBM) using Cellworks Singula: myCare-024-04. Ahluwalia MS, Castro MP, Watson D, et al. Journal of Clinical Oncology 2022, 40, no. 16_suppl; 2053-2053. DOI: 10.1200/JCO.2022.40.16_suppl.2053
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit. Castro, M., Pampana, A., Alam, A. et al. J Neurooncol (2021). https://doi.org/10.1007/s11060-021-03780-0;
Immunomic analysis of glioblastoma (GBM) using gene expression profiling. Michael P. Castro, Nilofar Badra-Azar, Thomas Kessler, Moritz Schütte, Bodo Lange, Marie-Laure Yaspo. Neuro-Oncology, Volume 22, Issue Supplement_2, 2020, ii5, https://doi.org/10.1093/neuonc/noaa215.016
Glutamate receptor and glutamine metabolism profiling by gene expression analysis among patients with high grade glioma (HGG). Michael P. Castro, Nilofar Badra-Azar, Thomas Kessler, Moritz Schütte, Bodo Lange, Marie-Laure Yaspo.. Neuro-Oncology, Volume 22, Issue Supplement_2, 2020, ii11, https://doi.org/10.1093/neuonc/noaa215.042
Major histocompatibility complex class 1 (MHC1) loss among patients with glioblastoma (GBM). Michael Castro, Bence Sipos, Natalia Pieper, Saskia Biskup; J Clin Oncol 38: 2020 (suppl; abstr e14523) DOI: 10.1200/JCO.2020.38.15_suppl.e14523
Combination chemotherapy versus temozolomide (TMZ) for patients with MGMT methylated (m-MGMT) glioblastoma (GBM): Results of Cellworks omics biosimulation—myCare-015. Michael Castro, Nirjhar Mundkur, Anusha Pampana, et al; J Clin Oncol 38: 2020 (suppl; abstr e14501). DOI: 10.1200/JCO.2020.38.15_suppl.e14501
Superior overall survival and disease free survival predictions for patients with glioblastoma multiform (GBM) using Cellworks Singula™ myCare-022-03. Wen PY, Castro M, Watson D et al (2021) J Clin Oncol 39 (suppl 15; abstr 2017)
Biomarker analysis of glioblastoma and potential implications for therapy. J Xiu, R Feldman, D Arguello, Z Gatalica, A Ghazalpour, R Bender, M Castro, S Reddy, G Basu, L Paul. J Clin Oncol 31, 2013 (suppl; abstr 2041)
Pharmacokinetics of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) Inhibitor in cerebrospinal fluid of a breast cancer patient with carcinomatous meningitis. M Castro, L Li, TE Stallings. Proc ASCO 2010, Abstract 48374
Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases in small cell carcinoma. MP Castro, S Quakman, T Odorisio, Cancer 2001, 91:2122-2126.
SOLID TUMORS
Advance testing for fatal toxicity: still in doubt? M. Castro LinkedIn Articles June 10,2024
Cellworks Singula therapy response index (TRI) predicts clinical outcomes for esophageal adenocarcinoma: MyCare-004. Smyth EC, Watson D, Nutzinger B, Castro MP, et al. DOI: 10.1200/JCO.2022.40.16_suppl.4064 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 4064-4064.
The utility of serial transcriptomic analyses to characterize the resistome and refine treatment selection for metastatic colon cancer: a case report. Michael P. Castro, Mohammad Afshar, Coralie Williams, Thomas Turcat, David Parker, Eva Gordon Jessica Zambelli, Amber MacDonald, Collen Suh, Sheley Baylon, and Saskia Biskup. Clinical Colorectal Cancer 2021, 20(1): 96-99. DOI: https://doi.org/10.1016/j.clcc.2020.10.003 https://www.clinical-colorectal-cancer.com/action/showPdf?pii=S1533-0028%2820%2930141-9
Computational Omics Biology Model (CBM) Identifies PD-L1 Immunotherapy Response Criteria Based on Genomic Signature of non-small cell lung cancer (NSCLC). M. Castro, A.K. Ganti, H. Grover, … V. Velcheti. World Lung cancer Congress, 2021, #995.
Impact of KRAS and Co-occurring Mutations on non-small cell lung cancer (NSCLC) Master Regulator Network as Determined by Computational Omics Biology Model. M. Castro, A.K. Ganti, A. Kuma, … V. Velcheti. World Lung Cancer Congress, 2021, #917.
Superior overall survival, progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare -022-05. Velcheti V, Castro M, Watson D, Kapoor S, et al. (2021) Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 9117-9117; DOI: 10.1200/JCO.2021.39.15_suppl.9117
Cellworks Omits Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance. Castro M, Kumar A, Grover H, et al. (2021). J Clin Oncol 39 Journal of Clinical Oncology 39, no. 15_suppl, e21208) DOI: 10.1200/JCO.2021.39.15_suppl.e21208
Cellworks Omits Biology Model (CBM predicts therapy response and identifies novel biomarkers for 5FU-based combinations therapy in gastric cancer patients. Kumar A, Velcheti V, Castro M, et al. (2021) Journal of Clinical Oncology 39, no. 15_suppl, )
Cellworks Omits Biology Model (CBM predicts therapy response and identifies novel biomarkers for carboplatin/cisplatin along with pemetrexed in NSCLC patients. Kumar A, Velchecti, Castro M., et al. (2021) Journal of Clinical Oncology 39, no. 15_suppl, e21211) DOI: 10.1200/JCO.2021.39.15_suppl.e21211
Synchronous onset of breast and pancreatic cancers: results of germline and somatic genetic analysis. Castro M., Vierkoetter K., Prager D., Montgomery S, Sedgwick K. Case Rep Oncol July 2016. DOI: 10.1159/000447348
The expression of programmed death ligand-1 (PD-L1) and use of PD-1 inhibitor-directed therapy with nivolomab in oral cavity cancer arising from recreational use of areca nut. M. Castro. Proc. American Society of Clinical Oncology (ASCO), Annual Meeting, June 2016. Abstract e17504.
Comprehensive genomic profiling of ovarian clear cell carcinomas identifies clinically relevant genomic alterations and targeted therapy options. Elvin JA, Chalmers ZR, Chudnovsky J, Sunl J, Hou J, Cat L, Ali SM, Virgilio JA, Suh J, Chimelecki J, Frampton J, del Priori G, Ross J, Gaillard S, Castro M, Wright J. Annual meeting, Society of Gynecologic Oncology. Poster presentation, March 20, 2016, San Diego
ABC transporter expression: Clues into chemoresistance of triple negative breast cancers. R Feldman, B Abbott, S Reddy, Z Gatalica, M Castro. Cancer Research 02/2016; 76(4 Supplement):P4-09-27-P4-09-27. DOI:10.1158/1538-7445.SABCS15-P4-09-27
Examination of Topoisomerase I (TOPO1) Expression in Metastatic GI Cancers. M Castro, R Feldman, SK Reddy. American Society of Clinical Oncology (ASCO) GI Symposium Poster presentation, January 2016.
Frequency of BRCA mutations and co-occurring alterations in Prostate Cancer. CE Myers R Feldman, BL Abbott, M.D., SK. Reddy, MP Castro, American Society of Clinical Oncology (ASCO) GU Symposium Poster presentation, January 2016.
Taxane sensitivity markers in prostate cancer. CE Myers, R Feldman, BL Abbott, SK Reddy, MP Castro. American Society of Clinical Oncology (ASCO) GU Symposium Poster presentation, January 2016.
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. MP Castro MP and N Goldstein N. Journal for the ImmunoTherapy of Cancer. 2015, 3:58
Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. MP Castro, B Whitcomb, D Zajkowski, R. Coleman. Gynecologic Oncology Research and Practice 2015, 2:4
Caveolin-1: Oncogenic role in breast cancer? Clues from molecular profiling. R Feldman, Z Gatalica, SK Reddy, M Castro, JC Sachdev. J Clin Oncol 33, 2015 (suppl 28S; abstr 134)
Drug efflux pump expression in 50,000 molecularly-profiled cancer patients. R. Feldman, B Abott, S Reddy, MP Castro. J Clin Oncol 33, 2015 (suppl; abstr 11108)
Expression patterns of a taxane sensitivity panel in 25,000 cancer patients. B Abott, R. Feldman, S Reddy, MP Castro. J Clin Oncol 33, 2015 (suppl; abstr e22235)
Metastatic Cancer of Cowper's Gland: A Rare Cancer Managed Successfully by Molecular Profiling. CE Myers, Z. Gatalica, A Spinelli, MP Castro, E. Linden O Sartor, M Sargeant. Case Rep Oncol. 2014 Jan 16;7(1):52-7. – 2014
Apocrine carcinoma of the breast: a comprehensive review. S. Vranic. S Schmitt, A Sapino, JL Costa, S Reddy, MP Castro, Z Gatalica. Histol Histopathol. 2013 Nov;28(11):1393-409.
Potential impact of different methodologies for detecting EGFR mutations in selecting chemotherapy for patients with lung cancer. R Bender, A Ghazalpour , Z Tan , Z Gatalica , L. Paul , SK. Reddy, MP Castro. J Clin Oncol 31, 2013 (suppl; abstr e19006)
Peripheral sensory neuropathy – fighting cold with cold. Castro MP Lancet Oncol 2008 9:415-6
Pharmacogenetics in the clinic: new questions about tamoxifen. Castro MP. J Oncol Practice 2006 2:100
Resisting a fundamentalist philosophy. M Castro J Clin Oncol. 2005 23:3645-46
Bisphosphonate-induced osteosclerosis. Castro MP, Novak S,Whyte MP. J Bone & Mineral Res 2005
Pharmacogenetic correlates of benefit from gemcitabine and platinum in patients with advanced bladder cancer. M Castro, A Neumann, M Konichexky, K Danneberg, S Stemmer Proc ASCO 2004 Abstrct 3203
Thymidine rescue: an antidote for pemetrexed related toxicity in the setting of acute renal failure. M. Castro, J Clin Oncol. 2003, 21:4066
Targeted Therapy. M. Castro in Heme-Onc Secrets, Edited by: M. Wood. University of Vermont Press 2003.
Timing is everything or could be. M. Castro J Clin Oncol. 21: 755, 2003.
The simpleton’s error in drug development. M. Castro. J Clin Oncol. 2002 20: 4606-7.
Eniluracil’s meed for a targeted approach: A lesson in drug development. M Castro. J Clin Oncol.2002 20: 3750.
Ex-vivo apoptotic assay (EVA)-directed use of gemcitabine as salvage therapy of colorectal carcinoma. M Castro. Lilly Oncology Investigators Meeting. Apr 4, 2002
Cyclophosphamide, 5-fluorouracil and prednisone (CFP) in hormone refractory prostate cancer. MP Castro, J Van Auken, N Oberhelman, RW Sponzo. Proc. ASCO 2000, 19:1435,
The impact of risk stratification on mammographic interpretation. R Sponzo, T Ashikaga, C Howland, P Cisek, MP Castro. Proc ASCO. 2000, 19:335.
Have the recently completed phase II trials impacted adjuvant treatment choices for stage II breast carcinoma? Middleman E, Castro MP, Gradisaw W. Semin Oncol, 1999, 26(4): XVI, XVII-XX,
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. MP Castro, S Legha, J Van Auken, P Cisek, RW Sponzo.Cancer 1999 85(5): 1055-9.
The efficacy of gemcitabine in the treatment of patients with gall bladder cancer. M. Castro, Cancer. 1998, 82(4): 639-41.
Clinicopathological correlations with mucin carbohydrate antigen expression in breast cancer. M. Castro, J. Strauchen, J. MAndeli, R. Perles, J. Morrison, S. Itzkowitz. Proc ASCO. 1991 10:200.
HEMATOLOGIC CANCERS
Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS). Michael Castro, MD, Shahabuddin Usmani, M.Sc., Ansu Kumar, M.Sc, et al. Blood (2022) 140 (Supplement 1): 4970–4971.
Cellworks Omits Biology Model (CBM) to predict response and identify biomarkers for all-transretinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML). Scott C. Howard, Ansu Kumar, Himanshu Grover,… Michael Castro C(2021) Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 7027-7027. DOI: 10.1200/JCO.2021.39.15_suppl.7027
Monosomy 7 and Co-occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): myCare-021-04. Michael P. Castro, Nirjhar Mundkur, Scott Howard, et al. American Society of Hematology 62nd ASH meeting, Dec 5 -8, 2020, Abstract 2906); https://ash.confex.com/ash/2020/webprogram/Paper140087.html
Prediction of clinical response for first line of treatment across AML patients using Cellworks Computational Biology Model. Michael Castro, Prashant Ramachandran Nair, Himanshu Grover. et al. (2020) Prediction of clinical response for frontline treatment of acute myeloid leukemia (AML) patients uniting the Cellworks Omits Biological Model (CBM): Mycare-021-02 62nd ASH meeting, Dec 5 -8, 2020, Abstract 2820; https://ash.confex.com/ash/2020/webprogram/Paper141479.html
The use of rituximab to manage B cell-mediated autoimmune thrombocytopenia (AITP) during concurrent program death ligand-1 (PD-L1) immunotherapy. M Castro. Proc. American Society of Clinical Oncology (ASCO), Annual Meeting, June 2016. Abstract e14545.
Successful use of anti-CD20 monoclonal antibody, rituximab, in patients with non-Hodgkins lymphoma and renal insufficiency. MP Castro, J Van Auken, RW Sponzo. PROC. ASCO2001, 20:3325.